# US 2025/0146019 A1 · Cd8 polypeptides, compositions, and methods of using thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146019 A1
- Document ID: US20250146019A1
- Status: Published application
- Kind: A1
- Application number: 19/020,283
- Filed: 2025-01-14
- Published: 2025-05-08
- Earliest claimed: 2020-12-31
- Assignees: Immatics US, Inc.
- Applicants: Immatics US, Inc.
- Inventors: Gagan BAJWA; Mamta KALRA; Melinda MATA
- Web page: https://patentgrep.com/patent/US20250146019A1

## CPC

- C12N 15/86: Viral vectors
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/427: {PRAME}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C12N 5/0636: {T lymphocytes}
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2810/55: from bacteria
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2840/203: having an IRES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods thereof.

## Claims

### Claim 1

A nucleic acid comprising a nucleic acid sequence encoding:
(i) a T-cell receptor (TCR) comprising a TCR α chain and a TCR β chain; and
(ii) a CD8 polypeptide comprising an amino acid sequence which is at least 95% identical to SEQ ID NO: 5, 258, 259, 262, or a variant thereof.

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein the TCR α chain and the TCR β chain are selected from SEQ ID NO: and 16, 17 and 18, 19 and 20, 21 and 22, 23 and 24, 25 and 26, 27 and 28, 29 and 30, 31 and 32, 33 and 34, 35 and 36, 37 and 38, 39 and 40, 41 and 42, 43 and 44, 45 and 46, 47 and 48, 49 and 50, 51 and 52, 53 and 54, 55 and 56, 57 and 58, 59 and 60, 61 and 62, 63 and 64, 65 and 66, 67 and 68, 69 and 70, 71 and 303, 304 and 74, 75 and 76, 77 and 78, 79 and 80, 81 and 82, 83 and 84, 85 and 86, 87 and 88, 89 and 90, and 91 and 92.

### Claim 3 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid sequence is at least 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleic acid sequence of SEQ ID NO: 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 295, 297, 299, or 301.

### Claim 4 (depends on 1)

A polypeptide encoded by the nucleic acid of claim 1.

### Claim 5

A polypeptide comprising an amino acid sequence which is at least 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 5, 258, 259, 262, or a variant thereof.

### Claim 6 (depends on 1)

A vector comprising the nucleic acid of claim 1.

### Claim 7 (depends on 6)

The vector of claim 6, wherein the vector further comprises a nucleic acid encoding a 2A peptide or an internal ribosome entry site (IRES) positioned between:
(i) the nucleic acid encoding the TCR α chain and the nucleic acid encoding the TCR β chain;
(ii) the nucleic acid encoding the TCR α chain and the nucleic acid encoding the CD8 polypeptide; and/or
(iii) the nucleic acid encoding the TCR β chain and the nucleic acid encoding the CD8 polypeptide.

### Claim 8 (depends on 7)

The vector of claim 7, wherein the 2A peptide is P2A (SEQ ID NO: 93), T2A (SEQ ID NO: 94), E2A (SEQ ID NO: 95), or F2A (SEQ ID NO: 96).

### Claim 9 (depends on 6)

The vector of claim 6, wherein the vector further comprises a posttranscriptional regulatory element (PRE) sequence selected from a Woodchuck PRE (WPRE), Woodchuck PRE (WPRE) mutant 1, Woodchuck PRE (WPRE) mutant 2, and hepatitis B virus (HBV) PRE (HPRE).

### Claim 10 (depends on 9)

The vector of claim 9, wherein the post-transcriptional regulatory element (PRE) sequence is (i) Woodchuck PRE (WPRE) mutant 1 comprising the amino acid sequence of SEQ ID NO: 256; or (ii) Woodchuck PRE (WPRE) mutant 2 comprising the amino acid sequence of SEQ ID NO: 257.

### Claim 11 (depends on 6)

The vector of claim 6, wherein the vector further comprises a promoter selected from cytomegalovirus (CMV) promoter, phosphoglycerate kinase (PGK) promoter, myelin basic protein (MBP) promoter, glial fibrillary acidic protein (GFAP) promoter, modified MoMuLV LTR comprising myeloproliferative sarcoma virus enhancer (MNDU3), Ubiquitin C promoter, EF-1 alpha promoter, and Murine Stem Cell Virus (MSCV) promoter.

### Claim 12 (depends on 6)

The vector of claim 6, wherein the vector is a viral vector or a non-viral vector.

### Claim 13 (depends on 12)

The vector of claim 12, wherein the viral vector is selected from adenoviruses, poxviruses, alphaviruses, arenaviruses, flaviviruses, rhabdoviruses, retroviruses, lentiviruses, herpesviruses, paramyxoviruses, picornaviruses, and combinations thereof.

### Claim 14 (depends on 12)

The vector of claim 12, wherein the viral vector is pseudotyped with an envelope protein of a virus selected from the native feline endogenous virus (RD114), a version of RD114 (RD114TR), gibbon ape leukemia virus (GaLV), a version of GaLV (GaLV-TR), amphotropic murine leukemia virus (MLV 4070A), baculovirus (GP64), vesicular stomatitis virus (VSV-G), fowl plague virus (FPV), Ebola virus (EboV), or baboon retroviral envelope glycoprotein (BaEV), and lymphocytic choriomeningitis virus (LCMV).

### Claim 15 (depends on 6)

The vector of claim 6, wherein the vector is a lentiviral vector.

### Claim 16 (depends on 6)

The vector of claim 6, wherein the vector further comprises a nucleic acid encoding a chimeric antigen receptor (CAR).

### Claim 17 (depends on 1)

AT cell transduced with the nucleic acid of claim 1.

### Claim 18 (depends on 17)

The T cell of claim 17, wherein the T cell is an αβ T cell, γδ T cell, and/or natural killer T cell.

### Claim 19 (depends on 18)

The T cell of claim 18, wherein the αβ T cell is a CD4+ T cell or a CD8+ T cell.

### Claim 20 (depends on 18)

The T cell of claim 18, wherein the γδ T cell is a Vγ9Vδ2+ T cell.

### Claim 21 (depends on 4)

A T cell expressing the polypeptide of claim 4.

### Claim 22 (depends on 21)

The T cell of claim 21, wherein said T cell is an αβ T cell, a γδ T cell, and/or a natural killer T cell.

### Claim 23 (depends on 21)

A composition comprising the T cell of claim 21.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the composition is a pharmaceutical composition.

### Claim 25 (depends on 23)

The composition of claim 23, wherein the composition further comprises an adjuvant, excipient, carrier, diluent, buffer, stabilizer, or a combination thereof.

### Claim 26 (depends on 1)

A method of preparing T cells for immunotherapy comprising isolating T cells from a blood sample of a human subject, activating the isolated T cells, transducing the activated T cells with the nucleic acid of claim 1, and expanding the transduced T cells.

### Claim 27 (depends on 23)

A method of treating a patient who has cancer, comprising administering to the patient the composition of claim 23, wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colorectal cancer, urinary bladder cancer, kidney cancer, leukemia, ovarian cancer, esophageal cancer, brain cancer, gastric cancer, and prostate cancer.

### Claim 28 (depends on 23)

A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient the composition of claim 23, wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colorectal cancer, urinary bladder cancer, kidney cancer, leukemia, ovarian cancer, esophageal cancer, brain cancer, gastric cancer, and prostate cancer.
